How effective are oral selective inhibitors of Janus kinase (JAK) for the treatment of pediatric atopic dermatitis (AD)?

Updated: Apr 26, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print

Baricitinib, an oral selective inhibitor of Janus kinase (JAK)–1 and JAK-2, which modulates proinflammatory cytokine signaling, appears to be have efficacy and be safe in patients with moderate-to-severe atopic dermatitis when used with topical steroids. [65]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!